for remission re-induction. Rituximab is favored based on the general desire to avoid re-treatment with cyclophosphamide if possible and on the findings of an observational study of rituximab in relapsing or refractory EGPA Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with rituximab, we conditionally recommend treatment with rituximab over switching to cyclophosphamide for remission